Vaxxas

Executive Summary

Vaxxas is a private biotechnology company developing a novel needle-free vaccination platform based on its High-Density Microarray Patch (HD-MAP) technology. The HD-MAP delivers vaccines directly to the immune-rich dermal and epidermal layers of the skin, potentially improving immunogenicity, dose-sparing, and thermostability compared to traditional injections. The platform is validated through partnerships with global health organizations (e.g., WHO, PATH) and pharmaceutical firms, targeting infectious diseases (influenza, COVID-19, HIV) and oncology. With a strong IP portfolio and preclinical data demonstrating broad immune responses, Vaxxas is positioned to address vaccine delivery challenges in both developed and resource-limited settings. The company is advancing its lead programs toward clinical trials and seeking additional partnerships to expand its pipeline.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase I clinical trial for HD-MAP influenza vaccine70% success
• Q2 2026Announcement of new strategic partnership with a top-10 pharmaceutical company for oncology vaccine delivery60% success
• Q3 2026Publication of peer-reviewed data demonstrating broad protection against multiple viral variants in preclinical models80% success